BioXcel Therapeutics is reporting full data from its Phase 2a trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer.
“These data support the further study of BXCL701 plus pembrolizumab in a Phase 2b trial for the potential treatment of small cell neuroendocrine prostate cancer,” said Rahul Aggarwal, M.D., Principal Investigator, Associate Director for Clinical Sciences, Helen Diller Family Comprehensive Cancer Center, and Associate Professor of Medicine at the University of California San Francisco (UCSF) … more
Earlier BioXcel announced that it will host a Key Opinion Leader Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET … more